Biostage, a Holliston-based biotech developing organ implants to treat cancers in the respiratory tract, said Monday it faces a possible delisting from the Nasdaq. But its CEO, a former top official at Genzyme, remains confident that the company will avoid that fate.
Biostage (Nasdaq: BSTG) said Monday it had received a letter from the exchange stating that it failed to meet two minimum requirements for listing: a $1 share price and $2.5 million in stockholders' equity. The 25-employee company said…
Biostage, a Holliston-based biotech developing organ implants to treat cancers in the respiratory tract, said Monday it faces a possible delisting from the Nasdaq. But its CEO, a former top official at Genzyme, remains confident that the company will avoid that fate.
Biostage (Nasdaq: BSTG) said Monday it had received a letter from the exchange stating that it failed to meet two minimum requirements for listing: a $1 share price and $2.5 million in stockholders' equity. The 25-employee company said…